A Long-term Follow-up Study of Patients Enrolled in ARD103_ARCE-CL-P-001 Phase 1/2 Study and Treated With ARD103 CAR-T Cell Therapies
Latest Information Update: 07 Apr 2025
At a glance
- Drugs ARD 103 (Primary)
- Indications Acute myeloid leukaemia; Myelodysplastic syndromes
- Focus Adverse reactions
- Sponsors ARCE Therapeutics
- 07 Apr 2025 New trial record